Find a Trial

Trial Results



Notice: Undefined index: DISEASE_SITE in /groups/cancint/web/newtrials/inc/list_sites.php on line 23
69 protocol(s) meet the specified criteria
14-13546OPEN TO ACCRUAL
Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients with Suspected Lower Respiratory Tract Infection
ADVL1514OPEN TO ACCRUAL
A PHASE 1 STUDY OF ABI-009 (NAB-RAPAMYCIN) IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN
BMTCTN1702OPEN TO ACCRUAL
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRLALT-D)
IUCRO-0049OPEN TO ACCRUAL
Immunologic, Genetic, Molecular, and Pathological Correlates with Clinical and Treatment Outcome in Patients with Renal Cell Carcinoma
IUCRO-0280OPEN TO ACCRUAL
IU Simon Cancer Center Tissue Bank
IUSCC-0601OPEN TO ACCRUAL
Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children
IUSCC-0678OPEN TO ACCRUAL
Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer
IUSCC-0696OPEN TO ACCRUAL
One-on-one exercise program in adolescent and young adult cancer survivors with a certified clinical cancer exercise specialist
PHO-BAYER-ADVL1721OPEN TO ACCRUAL
A non-randomized, open-label, multi-center, Phase I/II study of PI3K inhibitor copanlisib in pediatric patients with relapsed/refractory solid tumors or lymphoma
PHO-CIRM-ACESOPEN TO ACCRUAL
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701
PHO-COG-AALL1731OPEN TO ACCRUAL
Blinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic Lymphoma.
PHO-COG-AALL1732OPEN TO ACCRUAL
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
PHO-COG-AAML1831OPEN TO ACCRUAL
AAML1831, A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations.
PHO-COG-AAML18P1OPEN TO ACCRUAL
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
PHO-COG-ACCL1633OPEN TO ACCRUAL
ACCL1633, The Effectiveness of Lactobacillus plantarum in Preventing Acute Graft-versus-Host Disease (GvHD) in Children undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)
PHO-COG-ACNS1721OPEN TO ACCRUAL
A Phase 2 Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations
PHO-COG-ACNS1831OPEN TO ACCRUAL
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG).
PHO-COG-ACNS1833OPEN TO ACCRUAL
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
PHO-COG-ADVL1712OPEN TO ACCRUAL
Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome.
PHO-COG-ADVL1823OPEN TO ACCRUAL
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia.
PHO-COG-AGCT1532OPEN TO ACCRUAL
Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours
PHO-COG-AHEP1531OPEN TO ACCRUAL
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
PHO-COG-ANBL1531OPEN TO ACCRUAL
A Phase 3 Study of 131-I-Metaiodobenzylguanidine (131-I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)
PHO-COG-ANBL1821OPEN TO ACCRUAL
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma
PHO-COG-AREN1721OPEN TO ACCRUAL
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Axitinib or Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
PHO-COG-CROOP-ADVL1414OPEN TO ACCRUAL
A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors
PHO-COG-CROOP-ADVL1822OPEN TO ACCRUAL
A PHASE 1/2, MULTI-CENTER, DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF QUIZARTINIB ADMINISTERED IN COMBINATION WITH RE-INDUCTION CHEMOTHERAPY, AND AS A SINGLE-AGENT MAINTENANCE THERAPY, IN PEDIATRIC RELAPSED/REFRACTORY AML SUBJECTS AGED 1 MONTH TO < 18 YEARS (AND YOUNG ADULTS AGED UP TO 21 YEARS) WITH FLT3-ITD MUTATIONS
PHO-COG-CROOP-AINV18P1OPEN TO ACCRUAL
A PHASE 1 STUDY OF PALBOCICLIB (IND#141416), A CDK 4/6 INHIBITOR, IN COMBINATION WITH CHEMOTHERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) OR LYMPHOBLASTIC LYMPHOMA (LL)
PHO-COG-FALLON-AAML1531OPEN TO ACCRUAL
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
PHO-COG-FALLON-AGCT1531OPEN TO ACCRUAL
AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
PHO-COG-FALLON-ALTE03N1OPEN TO ACCRUAL
Key Adverse Events Following Childhood Cancer
PHO-COG-FALLON-ALTE07C1OPEN TO ACCRUAL
ALTE07C1, Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
PHO-COG-FALLON-ANBL00B1OPEN TO ACCRUAL
Neuroblastoma Biology Studies
PHO-COG-FALLON-ANBL1232OPEN TO ACCRUAL
ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma
PHO-COG-FALLON-ANHL12P1OPEN TO ACCRUAL
A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)
PHO-COG-FALLON-APEC14B1OPEN TO ACCRUAL
Project:EveryChild A Registry, Eligibility Screening, Biology and Outcome Study
PHO-COG-FALLON-AREN03B2OPEN TO ACCRUAL
Renal Tumors Classification, Biology, and Banking Study
PHO-COG-PEPN1812OPEN TO ACCRUAL
A PHASE 1 TRIAL OF THE CD123 X CD3 DUAL AFFINITY RE-TARGETING ANTIBODY FLOTETUZUMAB (NSC#808294, IND#145986) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
PHO-COG/EISAI-ADVL1711OPEN TO ACCRUAL
A Phase 1/2 Study of Lenvatinib in combination with Everolimus in Recurrent and Refractory Pediatric Solid Tumors, including CNS tumors
PHO-CROOP-AMGEN-20110261OPEN TO ACCRUAL
A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects with Advanced Non Central Nervous System Tumors That are Amenable to Direct Injection Advanced Non Central Nervous SystemTumors That are Amenable to Direct Injection
PHO-CROOP-COG-ADVL1615OPEN TO ACCRUAL
A PHASE 1 STUDY OF PEVONEDISTAT (MLN4924, IND# 136078), A NEDD8 ACTIVATING ENZYME (NAE) INHIBITOR, IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
PHO-EISAI-E7080-G000-230OPEN TO ACCRUAL
A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)
PHO-FALLON-COG-AALL1621OPEN TO ACCRUAL
AALL1621, A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
PHO-FALLON-COG-ARST1431OPEN TO ACCRUAL
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864, IND# 122782) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
PHO-FALON-INCYTE-AALL1521OPEN TO ACCRUAL
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway Mutant Acute Lymphoblastic Leukemia
PHO-IIR-INFECTIOUSDISEASEOPEN TO ACCRUAL
Infectious Disease Outcomes in Pediatric Oncology Patients.
PHO-IIR-IUSCC-0728OPEN TO ACCRUAL
Assessing the utility of ammonia levels as a tool for veno-occlusive disease (VOD) diagnosis.
PHO-JANSSEN-AALL2005OPEN TO ACCRUAL
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects 1 and 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
PHO-MERCK-KEYNOTE-667OPEN TO ACCRUAL
An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
PHO-NOVARTIS-CCTL019G2201JOPEN TO ACCRUAL
A phase II trial of tisagenlecleucel in first-line high-risk (HR) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who are minimal residual disease (MRD) positive at the end of consolidation (EOC) therapy
PHO-NOVARTISMAPS-SKILESOPEN TO ACCRUAL
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
PHO-PBMTC-ENDRADOPEN TO ACCRUAL
A phase II pilot trial to estimate survival after a non-total body irradiation (TBI) based conditioning regimen in patients diagnosed with B-acute lymphoblastic leukemia (ALL) who are pre-allogeneic hematopoietic cell transplantation (HCT) next-generation-sequence (NGS) minimal residual disease (MRD) negative
PHO-PFIZER-PRADHAN-ADVL1921OPEN TO ACCRUAL
PHO-PRADHAN-COG-AALL1631OPEN TO ACCRUAL
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
PHO-PRADHAN-COG-ACNS1422-OPEN TO ACCRUAL
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
PHO-PRADHAN-COG-ADVL1521OPEN TO ACCRUAL
A Phase 2 Study of the MEK Inhibitor Trametinib in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
PHO-PRADHAN-COG-ALTE1631OPEN TO ACCRUAL
A Randomized Web-based Physical Activity Intervention among Children and Adolescents with Acute Lymphoblastic Leukemia
PHO-PRADHAN-COG-ALTE16C1OPEN TO ACCRUAL
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma
PHO-PRADHAN-COG-APEC1621OPEN TO ACCRUAL
NCI-COG PEDIATRIC MATCH (MOLECULAR ANALYSIS FOR THERAPY CHOICE)MASTER VERSION CONTROL PROTOCOL
PHO-PRADHAN-MERK-ADVL1621OPEN TO ACCRUAL
A Phase I/II Study of Pembrolizumab (MK-3475) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma (KEYNOTE-051)
PHO-SEATTLE-PLAT-06OPEN TO ACCRUAL
Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-06: A Phase 1/2 Study of CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma.
PHO-SHIH-ASTRA-SELUMETINIOPEN TO ACCRUAL
An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas
PHO-SHIH-NWC-HEADSTART4OPEN TO ACCRUAL
NEWLY DIAGNOSED CHILDREN (LESS THAN 10 YEARS OLD) WITH MEDULLOBLASTOMA AND OTHER CENTRAL NERVOUS SYSTEM EMBRYONAL TUMORS: CLINICAL AND MOLECULAR RISK-TAILORED INTENSIVE AND COMPRESSED INDUCTION CHEMOTHERAPY FOLLOWED BY CONSOLIDATION WITH EITHER SINGLE CYCLE (LOW RISK PATIENTS) OR RANDOMIZATION (HIGH RISK PATIENTS) TO either SINGLE-CYCLE or TO THREE TANDEM CYCLES OF MARROW-ABLATIVE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE
PHO-STJUDE-AML16OPEN TO ACCRUAL
A PHASE II TRIAL OF EPIGENETIC PRIMING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
PHO-YMABS-201OPEN TO ACCRUAL
A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Primary or Secondary Refractory Osteomedullary Disease
PHO-YMABS-PRADHAN-101OPEN TO ACCRUAL
A Multicenter Phase 2/ 3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I-burtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
RAON-STANFORD-AVATAROPEN TO ACCRUAL
AVATAR anesthesia alternative in pediatric radiotherapy: A Multi-Center Pilot Study
SNEU-IIR-RIMTIHOPEN TO ACCRUAL
Role of Inflammatory Mediators in Tumor-Induced Hydrocephalus
SURG-IIR-COVID-19-RESPONSEOPEN TO ACCRUAL
Impact of the Initial COVID-19 Response and the Following Delayed Care Surge on Patients Requiring Emergent, Urgent, and Elective Surgical Procedures